MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
AURA — Aura Biosciences, Inc. Common Stock
NasdaqAura Biosciences, Inc. Common Stock
$6.09
+0.05(+0.83%)
- O
- 6.11
- H
- 6.15
- L
- 5.97
- V
- 2.1M
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About AURA
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
SectorNot available
IPO DateOct 29, 2021
Employees113
Stock ExchangeNasdaq
Ticker SymbolAURA
Key Financial Statistics
| Market Cap | $622.23M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $4.73 - $9.54 |
| 52-Week Avg Volume | 459.0K |
| VWAP | $6.04 |
| Transactions | 19,659 |
| Total Recorded Bars | 1,236 days |